Brief: FDA Approves Arcutis’(Roflumilast) Topical Foam, 0.3% For The Treatment Of Seborrheic Dermatitis In Individuals Aged 9 Years And Older
15/12/2023 23:28
Dec 15 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O :
* FDA APPROVES ARCUTIS’ ZORYVE® (ROFLUMILAST) TOPICAL FOAM,
0.3%
FOR THE TREATMENT OF SEBORRHEIC DERMATITIS IN INDIVIDUALS AGED 9
YEARS AND OLDER
* ARCUTIS BIOTHERAPEUTICS INC - COMMERCIAL PRODUCT EXPECTED
TO BE
AVAILABLE BY END OF JANUARY
Source text for Eikon: ID:nGNXbCWwqN
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf